Hormonal therapy—like tamoxifen or aromatase inhibitors—is one of the most powerful treatments for hormone receptor-positive breast cancer. For many people, these medicines work for years to keep cancer under control.
Sometimes, though, the cancer learns to grow in a new way, even while you are still taking these medications. That can feel frightening, but it does not mean you are out of options.
One of the reasons this can happen is something called an ESR1 mutation. Let’s talk about what that means, and why it matters, in the simplest way possible.
Think of cancer cells as very clever. When we block estrogen with medicines like tamoxifen, most of the cancer cells slow down. But some of them can find a new way to turn the “on” switch back on—even when there is little estrogen left in your body.
They do this by changing a part of themselves called the ESR1 gene, which makes the estrogen receptor. Once that part changes, those cancer cells can keep growing, even without much estrogen.
If your cancer develops this mutation, the usual hormonal therapy may not be as strong as it used to be.
The good news is that doctors now have a way to test for these changes and can use that information to switch to medicines that still work.
The test is often simple:
These tests help your care team understand what your cancer is doing now—not just what it did when you were first diagnosed. (Learn more about pathology and testing).
This is where new medicines and research give us hope.
There are newer drugs called SERDs (Selective Estrogen Receptor Degraders) that are specially designed to block and break down estrogen receptors—even the mutated ones.
One of these medicines, elacestrant, was approved in 2023. Others—like camizestrant and imlunestrant—are in clinical trials right now.
These treatments are often combined with other targeted therapies to give you the best chance of keeping the cancer under control.
“Detecting ESR1 mutations gives us a roadmap. It tells us when a cancer has found a way around standard treatment—and helps us pivot to a therapy that can still work. This is the power of precision medicine. It’s why staying engaged with your care team, even years after finishing treatment, matters so much.”
– Rahul Singh, MD
Medical Oncologist & Learn Look Locate Medical Advisor
It’s worth talking with your doctor about ESR1 testing if:
It can be overwhelming to hear that your treatment may no longer be working. But an ESR1 mutation does not close the door—it opens a new one.
Testing for this mutation allows your care team to change direction and choose a treatment that has a better chance of working for you.
Every year, researchers are finding better ways to outsmart these mutations. Knowing about ESR1 gives us one more way to stay ahead.
Q. What does ESR1 mean?
A: It’s the gene that makes the estrogen receptor in breast cells.
Q. Does everyone with breast cancer develop ESR1 mutations?
A: No. Only some cancers develop these changes, often after being on hormonal therapy for a while.
Q. Can ESR1 mutations be treated?
A: Yes. New medicines like elacestrant and other SERDs are made specifically for this type of change.
Moving Forward With Knowledge and Hope
If you ever hear the term ESR1 during your breast cancer journey, know this: it is a sign that your care is becoming more personal and more precise.
Knowledge like this gives your doctors more tools to help you—and more hope for the future.
Share This Story, Choose Your Platform!